| |
| |
| Exchange: |
New York Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
956,580,000 |
| Market
Cap: |
869.57(B) |
| Last
Volume: |
1,947,382 |
Avg
Vol: |
3,268,697 |
| 52
Week Range: |
$434.7 - $909.04 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NYSE COMPOSITE |
| |
S&P 500 |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 720 |
| Guru Rank Value : 1.4 |
| Guru Occurances : 2 |
|
|
|
|
|
| |
|
Company Profile Eli Lilly and Company discovers, develops, manufactures, and markets products in a single business segment: human pharmaceutical products. Co.'s products include: diabetes products, oncology products, immunology products, neuroscience products, and other therapies. Co.'s diabetes products include: Baqsimi®, Basaglar®, Humalog®, Humulin®, Jardiance®, Lyumjev®, Trajenta®, and Trulicity®. Co.'s oncology products include: Alimta®, Cyramza®, Erbitux®, Retevmo®, Tyvyt®, and Verzenio®. Co.'s immunology products include: Olumiant® and Taltz®. Co.'s neuroscience products include: Cymbalta®, Emgality®, Reyvow®, and Zyprexa®. Co.'s other therapies include: Bamlanivimab, Cialis®, and Forteo®.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
656 |
| Total Buy Value |
$0 |
$0 |
$0 |
$199,549 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
1,520,577 |
2,391,327 |
3,815,444 |
6,318,238 |
| Total Sell Value |
$1,284,658,855 |
$1,892,909,435 |
$2,147,483,647 |
$2,147,483,647 |
| Total People Sold |
3 |
3 |
4 |
6 |
| Total Sell Transactions |
18 |
31 |
51 |
93 |
| End Date |
2024-03-30 |
2023-12-28 |
2023-06-29 |
2022-06-29 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Simmons Jeffrey N |
SVP&Pres. Elanco Animal Health |
• – – |
2018-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
21,326 |
152,120 |
|
- |
|
| Fry Stephen F |
SVP, HR & Diversity |
• – – |
2018-02-01 |
4 |
D |
$81.45 |
$619,753 |
D/D |
(7,609) |
100,211 |
|
- |
|
| Fry Stephen F |
SVP, HR & Diversity |
• – – |
2018-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
17,060 |
107,820 |
|
- |
|
| Conterno Enrique A |
SVP&Pres, LillyDiab & LillyUSA |
• – – |
2018-02-01 |
4 |
D |
$81.45 |
$774,752 |
D/D |
(9,512) |
138,468 |
|
- |
|
| Conterno Enrique A |
SVP&Pres, LillyDiab & LillyUSA |
• – – |
2018-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
21,326 |
147,980 |
|
- |
|
| Lundberg Jan M |
EVP,Science&Tech and Pres. LRL |
• – – |
2018-02-01 |
4 |
D |
$81.45 |
$1,316,965 |
D/D |
(16,169) |
198,126 |
|
- |
|
| Lundberg Jan M |
EVP,Science&Tech and Pres. LRL |
• – – |
2018-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
36,252 |
214,295 |
|
- |
|
| Zulueta Alfonso G |
SVP & President, Lilly Intl |
• – – |
2018-02-01 |
4 |
D |
$81.45 |
$580,983 |
D/D |
(7,133) |
58,224 |
|
- |
|
| Zulueta Alfonso G |
SVP & President, Lilly Intl |
• – – |
2018-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,993 |
65,357 |
|
- |
|
| Mahony Susan |
SVP & Pres., Lilly Oncology |
• – – |
2018-02-01 |
4 |
D |
$81.45 |
$776,463 |
D/D |
(9,533) |
50,817 |
|
- |
|
| Mahony Susan |
SVP & Pres., Lilly Oncology |
• – – |
2018-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
21,326 |
60,350 |
|
- |
|
| Ricks David A |
President & CEO |
• • – |
2018-02-01 |
4 |
GD |
$0.00 |
$0 |
D/D |
11,764 |
119,486 |
|
- |
|
| Ricks David A |
President & CEO |
• • – |
2018-02-01 |
4 |
D |
$81.45 |
$778,581 |
D/D |
(9,559) |
131,250 |
|
- |
|
| Ricks David A |
President & CEO |
• • – |
2018-02-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
21,326 |
140,809 |
|
- |
|
| Oneill Myles |
SVP & Pres., Mfg. Operations |
• – – |
2018-01-29 |
4 |
A |
$87.60 |
$374,840 |
I/I |
4,279 |
70,638 |
|
- |
|
| Mahony Susan |
SVP & Pres., Lilly Oncology |
• – – |
2018-01-29 |
4/A |
A |
$87.60 |
$119,574 |
I/I |
1,365 |
14,874 |
|
- |
|
| Conterno Enrique A |
SVP&Pres, LillyDiab & LillyUSA |
• – – |
2018-01-29 |
4 |
A |
$87.60 |
$1,089,481 |
D/D |
12,437 |
126,654 |
|
- |
|
| Barnes Melissa S |
Chief Eth/Cmpl Ofcr & SVP, ERM |
• – – |
2018-01-29 |
4 |
A |
$87.60 |
$329,288 |
D/D |
3,759 |
15,709 |
|
- |
|
| Lundberg Jan M |
EVP,Science&Tech and Pres. LRL |
• – – |
2018-01-29 |
4 |
A |
$87.60 |
$2,005,164 |
D/D |
22,890 |
178,043 |
|
- |
|
| Zulueta Alfonso G |
SVP & President, Lilly Intl |
• – – |
2018-01-29 |
4 |
A |
$87.60 |
$816,082 |
D/D |
9,316 |
49,364 |
|
- |
|
| Shah Aarti S. |
SVP & CIO |
• – – |
2018-01-29 |
4 |
A |
$87.60 |
$251,237 |
D/D |
2,868 |
15,709 |
|
- |
|
| Mahony Susan |
SVP & Pres., Lilly Oncology |
• – – |
2018-01-29 |
4 |
A |
$87.60 |
$119,399 |
I/I |
1,363 |
14,872 |
|
- |
|
| Mahony Susan |
SVP & Pres., Lilly Oncology |
• – – |
2018-01-29 |
4 |
A |
$87.60 |
$1,087,291 |
D/D |
12,412 |
51,436 |
|
- |
|
| Harrington Michael J |
Senior VP and General Counsel |
• – – |
2018-01-29 |
4 |
A |
$87.60 |
$1,415,441 |
D/D |
16,158 |
78,214 |
|
- |
|
| Smiley Joshua L |
SVP and CFO |
• – – |
2018-01-29 |
4 |
A |
$87.60 |
$630,895 |
D/D |
7,202 |
23,029 |
|
- |
|
1436 Records found
|
|
Page 37 of 58 |
|
|
7.78 (0.86%) 
